EPAS1 and prostate carcinoma: Another potential advantage of targeting AR-suppressed miR-145 signals may come from the profound AR effects to suppress RCC progression that suppression of HIF2α-VEGF signal alone may not be able to have, and early studies using ASC-J9® to suppress AR-mediated prostate cancer/bladder cancer progression all resulted in reasonable efficacy with little side effects in tested mice [37].